Clinical Trials Browser

Phase 2 × Esophageal Neoplasms × Platinum Compounds × Clear all

NCT06231680 2024-03-29

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Phase 2 Unknown

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms